eISSN: 2084-9834
ISSN: 0034-6233
Reumatologia/Rheumatology
Current issue Archive About the journal Supplements Editorial board Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
SCImago Journal & Country Rank
 
6/2009
vol. 47
 
Share:
Share:
more
 
 
abstract:
Review paper

Ibandronate in prevention of osteoporotic fractures

Edward Czerwiński
,
Jolanta Osieleniec

Reumatologia 2009; 47, 6: 356-359
Online publish date: 2010/04/08
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Bisphosphonates are among the drugs most frequently used in osteoporosis; however, due to their low bioavailability and incon-venient way of administration, only 44.2% of patients continue the weekly therapy after a year. Ibandronate is a new aminobis-phosphonate which can be administered in a dose of 150 mg orally once monthly and 3 mg intravenously once in 3 months. In the article clinical trials (BONE, MOBILE, DIVA) are discussed, which have proved that ibandronate efficiently reduces the risk of spinal and non-vertebral fractures and can be safely used in the treatment of osteoporosis.
The results of the VIBE study are also presented, showing a lack of difference in the incidence of proximal femur fractures and sig-nificantly lower incidence of vertebral fractures in the group of patients treated with ibandronate once monthly, as compared to alendronate once weekly.
The simple schema of the dosage of ibandronate with long breaks between consecutive doses has a beneficial effect on adherence to treatment procedures and length of the therapy of osteoporosis.
keywords:

fractures, osteoporosis, ibandronate, bisphosphonates, intravenous bisphosphonates



Quick links
© 2020 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe